| HEMATOLOGICAL MALIGNANCIES - REVIEW ARTICLE |
|
| Year : 2011 | Volume
: 48
| Issue : 4 | Page : 438-445 |
Nilotinib as first-line therapy for chronic myeloid leukemia
A Vaid
Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi, India
Correspondence Address:
A Vaid
Department of Medical Oncology, Cancer Institute, Medanta Hospital, Medicity, Sector 38, Gurgaon, NCR, Delhi
India
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.4103/0019-509X.92274
Tyrosine Kinase Inhibitors brought a revolution in the management of chronic myeloid leukemia. Long term disease free survival became a reality for the majority of patients. With the identification of imatinib resistance and its implications, roles of newer targeted therapy molecules came into focus. Nilotinib data has matured and shows the fulfillment of earlier promise - even in first line therapy. This review provides insight into the place of this molecule in the first line management of chronic myeloid leukemia.
[FULL TEXT] [PDF]*
|
